Author Archives: Bruno Quinney

#Drug discovery #Patent Law

From risk to resilience

Peng Fu, CEO, and Estrid Jakobsen, Communications Lead at Conscience, explore how creativity and open science are transforming drug discovery.   The traditional drug discovery model is showing signs of strain. The cost of developing new medicines continues to rise while early-stage funding is becoming harder to secure, timelines remain… Read More

#Exclusive Content

#DDW Highlights podcast

DDW Highlights: 14 October 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, the Nobel Prize for Physiology or Medicine was awarded to three… Read More

#Podcasts

This week in Drug Discovery (6 – 10 October)

News round-up for 6 – 10 October by Bruno Quinney, Content Team at DDW.  In the week that the recipients of the Nobel Prizes are being announced, the prize for Physiology or Medicine has been given to three scientists for their discovery on regulatory T cells. Elsewhere,… Read More

#News

Respiratory system
#FDA #Idiopathic pulmonary fibrosis

FDA approves nerandomilast tablets to treat IPF

The US Food and Drug Administration (FDA) has approved Boehringer’s Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis (IPF).  Jascayd is an oral treatment option for adult patients with IPF, becoming the first and only preferential inhibitor of phosphodiesterase 4B (PDE4B) to be approved in this indication. This represents a… Read More

#News #Regulatory

#Cancer research #Oncology #The Francis Crick Institute #Vividion Therapeutics

Research identifies compounds preventing cancer gene mutation

New research has identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS and a key pathway for tumour growth.   Researchers from the Francis Crick Institute and Vividion Therapeutics identified compounds that can block the RAS gene from mutating without preventing the… Read More

#News

#Artificial intelligence (AI) #Drug discovery

Accelerating drug discovery with technology 

David Nirschl, Head, Life Sciences Consulting, Thermo Fisher Scientific and Santosh Vijay, Senior Director, Program Management, Thermo Fisher Scientific explore how to harness innovation for speed, scale and personalisation in the lab.  The drug discovery journey has always been complex, and as scientists have moved from one hypothesis to the… Read More

#Exclusive Content

#AI #Clinical trial

AI creating ‘measurable gains’ in clinical trials, new data reveals

Over 70% of artificial intelligence (AI) users in clinical trials see measurable gains in study speed, data analytics brand Medidata has revealed.  The findings come from a new global research report, ‘The State of AI In Clinical Trials: Today and Tomorrow’, which investigates how AI is redesigning… Read More

#News

Laboratory research
#Clinical trial #Orexa

Positive interim data announced in clinical trial of POI treatment

Life sciences company Orexa has announced positive interim data for its Phase II trial evaluating ORE-001, a treatment for the prevention of post-operative ileus (POI) in patients undergoing major abdominal surgery.  Interim analysis was conducted after 40 patients were randomised. The data demonstrated that ORE-001 could be… Read More

#News

Neuroscience Parkinson's disease
#Parkinson's

Positive results announced for Parkinson’s treatment ARV-102  

Biotechnology company Arvinas has announced positive results for its Phase I clinical trial of ARV-102 in Parkinson’s disease.  The results, presented at the International Congress of Parkinson’s Disease and Movement Disorders in Honolulu, show positive pharmacokinetic, pharmacodynamic, and biomarker data from two Phase I clinical trials evaluating… Read More

#News

#Antibody #Genetics

FairJourney Biologics appoints Dr Werner Lanthaler as CEO

Biotechnology company FairJourney Biologics has appointed Dr Werner Lanthaler as Chief Executive Officer (CEO), the company has announced.   Lanthaler has forged an extensive career in the biopharmaceutical industry, driving innovation, transformation and sustainable growth. Lanthaler served as CEO of Evotec SE for 15 years, where he… Read More

#News

#Cancer research #Gene therapy #Long Covid

This week in Drug Discovery (29 September – 3 October)

News round-up for 29 September – 3 October by Bruno Quinney, Content Team at DDW.  This week’s news is led by the agreement by Genmab to acquire Merus in a deal worth approximately $8 billion, an announcement which could have important ramifications in cancer research. Scientists have… Read More

#News

Chronic gout
#Crystalys Therapeutics #Financing #Gout #Start-ups

Crystalys Therapeutics launches to develop gout treatment

Biopharmaceutical company Crystalys Therapeutics has launched with a $205 million Series A financing round, aiming to address the significant unmet medical needs of people living with gout.   The financing round was co-led by Novo Holdings, SR One and Catalys Pacific with participation from a broad syndicate of investors, including Perceptive… Read More

#Business & Investment #News #Start-up Zone

#Autoimmune disease #Diabetes #Mergers and acquisitions #Metabolic diseases

Barinthus Bio and Clywedog Therapeutics announce merger

Immunology and inflammation company Barinthus Biotherapeutics and private company Clywedog Therapeutics will merge to target metabolic and autoimmune diseases, the companies have announced.  The combined company, named Clywedog Therapeutics, will now advance a novel portfolio of clinical-stage candidates targeting metabolic and autoimmune diseases. The portfolio includes three differentiated, clinical stage… Read More

#Business & Investment #News

#Antibiotics #Antimicrobial resistance (AMR) #Antimicrobials #Drug resistance

PACE launches new funding for antimicrobial drug development

PACE, one of the UK’s largest public-private initiatives targeting early-stage antimicrobial drug and diagnostic development, has launched its third round of funding to support innovative projects.  The initiative has announced £6 million ($8 million) in funding for antibacterial treatment innovations, aiming to tackle resistant bacterial infections and… Read More

#News

#AbbVie #Brain disease #Collaboration #Nxera Pharma

Nxera Pharma receives $10 million from collaboration with AbbVie

Nxera Pharma has received $10 million from pharmaceutical company AbbVie under the terms of the multi-target discovery collaboration on neurological diseases, Nxera has announced.  Nxera and AbbVie entered the multi-target collaboration in 2022, leveraging Nxera’s NxWave platform to discover novel medicines targeting G protein-coupled receptors (GPCRs) associated with neurological disease. Read More

#Business & Investment #News